This article is rated C-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||||||||||||||||||||||||||
|
Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Tetrahydrobiopterin.
|
On 24 June 2022, it was proposed that this article be moved to Sapropterin. The result of the discussion was no consensus. |
I don't have time to learn how to edit this page right now.
But I noticed the chemical structure of tetrahydrobiopterin is wrong. There are 5 things bonded to the carbon. The correct structure is actually back in the history of this article a few edits ago.... with the N in the ring that's double bonded to the carbonele .... should actually be an NH - single bonded to the carbonele (because it's impossible to have it according to the way the curren png picture shows).
I noticed that the figure actually is for sapropterin, not for tetrahydrobiopterin. Tetrahydrobiopterin should have a protonated nitrogen at the 3 position for the fully reduced form. The nitrogen at the 1 position should actually not be protonated and should have a double bond to the carbon at the 2 position. —Preceding
unsigned comment added by
128.197.112.231 (
talk)
23:04, 18 March 2008 (UTC)
The structure given in the file -- showing a proton at N-1 (at the bottom left as drawn) is correct, per Chemical Abstract Service and USAN nomenclature. Sapropterin exists as a tautomer; much of the "tetrahydrobiopterin" literature, historically, has used the alternative tautomer, with the N-3 nitrogen protonated instead of the N-1. Either structure is acceptable. The advantage of using the term "sapropterin" rather than "tetrahydrobiopterin" or "BH4" is simple: by definition, sapropterin means the 6R stereochemistry; tetrahydrobiopterin and BH4 are ambiguous terms. —Preceding unsigned comment added by 64.84.58.84 ( talk) 16:35, 6 May 2008 (UTC)
Also, i have heard this can be used in treating the skin disorder vitiligo, which i suffer from. It has trialled 90% successfully in america and my doctor is now looking to see if i can get it on the NHS —Preceding unsigned comment added by Andyjlaidlaw ( talk • contribs) 22:29, 22 July 2010 (UTC)
I have a genetic disorder on GCH1 which causes a deficiency in BH4 production - I am therefore unfortunately more familiar with BH4 than I'd like to be. As I am not a biochemist, I merely added "citation needed" at the end of the first sentence instead of fixing it - BH4 is not involved in the production of those neurotransmitters, however. Instead of changing current content, I opted for adding additional content (added "other clinical issues").
This entry (and the one about Tetrahydrobiopterin_Deficiency) unfortunately reads like an advertisement for BioMarin and what the FDA has approved Kuvan to be prescribed for; BH4 has many roles that are *exceptionally* more important than treating toxic levels of L-Phenylalanine. That role isn't really a "role" - it's a byproduct of proper biosynthesis of L-Tyrosine which is directly, not indirectly, needed. The vast majority of clinical issues resultant from BH4 deficiency happen long before toxic levels of L-Phenylalanine in the blood, which itself can be alternately treated (as it was, until 2007) by simply lowering the intake of that amino acid - but would still leave a patient with dangerously low levels of L-Dopa and would leave all the other conditions (which are all indirectly caused by the low BH4 levels) still completely untreated. I can avoid L-Phenylalanine in my diet (I don't need to, as my levels aren't high enough to be toxic), but that won't make my dystonia go away. Note that 99% of PKU is not caused by BH4 deficiency, either (Biomarin's own research); one could have PKU and not have any issues with Dopamine levels.
This isn't meant as a harsh to Kuvan/Biomarin; I'd take it if my physician wasn't hesitant to prescribe it in concert with Sinemet. Suggesting BH4 is primarily vital for reduction of L-Phenylalanine levels is very misleading however, in my (admittedly not classically trained) opinion. Taking Kuvan, the drug, is approved primarily for PKU treatment. The two things are not analogous - the FDA doesn't define the deep medical Truths we hope humanity one day discovers. Brianlamere ( talk)
There is paper showing that BH4 is a cofactor for NO synthases "The Three Nitric-oxide Synthases Differ in Their Kinetics of Tetrahydrobiopterin Radical Formation, Heme-Dioxy Reduction, and Arginine Hydroxylation*" by Chin-Chuan Wei et al, published in 2005. I've seen papers citing the role as cofactors for the enzymes necessary for making neurotransmitter precursors, but I don't have a copy of it on my computer. I'll post the titles / authors here if I can find them. —Preceding unsigned comment added by 65.47.29.74 ( talk) 21:19, 2 May 2011 (UTC)
The result of the move request was: no consensus. ( closed by non-admin page mover) Vpab15 ( talk) 16:50, 18 July 2022 (UTC)
Tetrahydrobiopterin → Sapropterin – Use the INN for the page name per WP:MEDMOS, WP:PHARMMOS Whywhenwhohow ( talk) 20:14, 24 June 2022 (UTC)— Relisting. Usernamekiran ( talk) 21:42, 1 July 2022 (UTC) — Relisting. — Ceso femmuin mbolgaig mbung, mello hi! ( 投稿) 00:53, 10 July 2022 (UTC)
This article is rated C-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||||||||||||||||||||||||||
|
Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Tetrahydrobiopterin.
|
On 24 June 2022, it was proposed that this article be moved to Sapropterin. The result of the discussion was no consensus. |
I don't have time to learn how to edit this page right now.
But I noticed the chemical structure of tetrahydrobiopterin is wrong. There are 5 things bonded to the carbon. The correct structure is actually back in the history of this article a few edits ago.... with the N in the ring that's double bonded to the carbonele .... should actually be an NH - single bonded to the carbonele (because it's impossible to have it according to the way the curren png picture shows).
I noticed that the figure actually is for sapropterin, not for tetrahydrobiopterin. Tetrahydrobiopterin should have a protonated nitrogen at the 3 position for the fully reduced form. The nitrogen at the 1 position should actually not be protonated and should have a double bond to the carbon at the 2 position. —Preceding
unsigned comment added by
128.197.112.231 (
talk)
23:04, 18 March 2008 (UTC)
The structure given in the file -- showing a proton at N-1 (at the bottom left as drawn) is correct, per Chemical Abstract Service and USAN nomenclature. Sapropterin exists as a tautomer; much of the "tetrahydrobiopterin" literature, historically, has used the alternative tautomer, with the N-3 nitrogen protonated instead of the N-1. Either structure is acceptable. The advantage of using the term "sapropterin" rather than "tetrahydrobiopterin" or "BH4" is simple: by definition, sapropterin means the 6R stereochemistry; tetrahydrobiopterin and BH4 are ambiguous terms. —Preceding unsigned comment added by 64.84.58.84 ( talk) 16:35, 6 May 2008 (UTC)
Also, i have heard this can be used in treating the skin disorder vitiligo, which i suffer from. It has trialled 90% successfully in america and my doctor is now looking to see if i can get it on the NHS —Preceding unsigned comment added by Andyjlaidlaw ( talk • contribs) 22:29, 22 July 2010 (UTC)
I have a genetic disorder on GCH1 which causes a deficiency in BH4 production - I am therefore unfortunately more familiar with BH4 than I'd like to be. As I am not a biochemist, I merely added "citation needed" at the end of the first sentence instead of fixing it - BH4 is not involved in the production of those neurotransmitters, however. Instead of changing current content, I opted for adding additional content (added "other clinical issues").
This entry (and the one about Tetrahydrobiopterin_Deficiency) unfortunately reads like an advertisement for BioMarin and what the FDA has approved Kuvan to be prescribed for; BH4 has many roles that are *exceptionally* more important than treating toxic levels of L-Phenylalanine. That role isn't really a "role" - it's a byproduct of proper biosynthesis of L-Tyrosine which is directly, not indirectly, needed. The vast majority of clinical issues resultant from BH4 deficiency happen long before toxic levels of L-Phenylalanine in the blood, which itself can be alternately treated (as it was, until 2007) by simply lowering the intake of that amino acid - but would still leave a patient with dangerously low levels of L-Dopa and would leave all the other conditions (which are all indirectly caused by the low BH4 levels) still completely untreated. I can avoid L-Phenylalanine in my diet (I don't need to, as my levels aren't high enough to be toxic), but that won't make my dystonia go away. Note that 99% of PKU is not caused by BH4 deficiency, either (Biomarin's own research); one could have PKU and not have any issues with Dopamine levels.
This isn't meant as a harsh to Kuvan/Biomarin; I'd take it if my physician wasn't hesitant to prescribe it in concert with Sinemet. Suggesting BH4 is primarily vital for reduction of L-Phenylalanine levels is very misleading however, in my (admittedly not classically trained) opinion. Taking Kuvan, the drug, is approved primarily for PKU treatment. The two things are not analogous - the FDA doesn't define the deep medical Truths we hope humanity one day discovers. Brianlamere ( talk)
There is paper showing that BH4 is a cofactor for NO synthases "The Three Nitric-oxide Synthases Differ in Their Kinetics of Tetrahydrobiopterin Radical Formation, Heme-Dioxy Reduction, and Arginine Hydroxylation*" by Chin-Chuan Wei et al, published in 2005. I've seen papers citing the role as cofactors for the enzymes necessary for making neurotransmitter precursors, but I don't have a copy of it on my computer. I'll post the titles / authors here if I can find them. —Preceding unsigned comment added by 65.47.29.74 ( talk) 21:19, 2 May 2011 (UTC)
The result of the move request was: no consensus. ( closed by non-admin page mover) Vpab15 ( talk) 16:50, 18 July 2022 (UTC)
Tetrahydrobiopterin → Sapropterin – Use the INN for the page name per WP:MEDMOS, WP:PHARMMOS Whywhenwhohow ( talk) 20:14, 24 June 2022 (UTC)— Relisting. Usernamekiran ( talk) 21:42, 1 July 2022 (UTC) — Relisting. — Ceso femmuin mbolgaig mbung, mello hi! ( 投稿) 00:53, 10 July 2022 (UTC)